Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Crispr Therapeutics AG (CRSP) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance

Crispr Therapeutics AGTrade
DENTSPLY SIRONA IncTrade

Price performance (Past 24H)

Key statistics

Crispr Therapeutics AG vs DENTSPLY SIRONA Inc — how do they compare? Crispr Therapeutics AG trades at $54.3 (market cap $5.23B), while DENTSPLY SIRONA Inc trades at $11.66 (market cap $2.31B). The key difference: Crispr Therapeutics AG is far larger — about 2.3× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.

CRSPXRAY
Market Cap
$5.23B$2.31B
Sector
HealthHealth
52-Week High
$76.78$14.68
52-Week Low
$44.34$9.64
Enterprise Value
$3.65B$4.39B
Dividend Yield
5.04%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Crispr Therapeutics AG

CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.

Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.

DENTSPLY SIRONA Inc

DENTSPLY SIRONA (XRAY) trades at $11.66, down 3.8% on the day, with a bearish technical outlook and mixed fundamentals. The stock faces headwinds from declining revenue and negative profitability, though Q2 2026 earnings beat expectations. Recent news highlights institutional stake increases and ongoing turnaround efforts amid weak dental market conditions.

The outlook remains challenging with persistent net losses and high debt, but cost controls and strategic partnerships offer potential stabilization. Risks include competitive pressures and macroeconomic softness, while analyst consensus is Hold with a $11.50 price target, suggesting limited near-term upside.

Returns comparison

Trailing returns across standard periods

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP

About DENTSPLY SIRONA Inc

Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters

Read more on XRAY